Outlook Therapeutics, Inc. Q3 2026 Earnings Recap

Shares of Outlook Therapeutics plunged 24.4% following the quarter as investors reacted negatively to cautious commercial outlook and significant execution risks ahead despite FDA approval. The stock selloff reflects skepticism about the company’s ability to convert regulatory success into meaningful near-term revenue growth.

Key Takeaways

• FDA approved LYTENAVA, the first ophthalmic formulation of bevacizumab for wet AMD in the U.S., marking a regulatory milestone.
• The total U.S. anti-VEGF retina market is estimated at $8.5 billion annually, with approximately 3.6 million injections of repackaged bevacizumab forecast in 2025.
• Management projects LYTENAVA could generate over $500 million in peak annual sales by 2030 but emphasized this as a long-term goal requiring strong execution.
• Key risks include uncertain commercial adoption dynamics, need for payer partnerships, access and reimbursement hurdles, and supply chain reliability.
• No concrete near-term revenue or volume guidance was provided, highlighting the early stage of commercialization and investor caution.